Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

EPROSARTAN MESYLATE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable

  • Candesartan cilexetil (Atacand): general benefit
  • Irbesartan (Avapro): general benefit, Not a benefit
  • Losartan (Cozaar): general benefit
  • Olmesartan medoxomil (Olmetec): general benefit
  • Telmisartan (Micardis): general benefit
  • Valsartan (Diovan): general benefit, Not a benefit

Teveten · DIN 02240432 · 400mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.Discontinued 2023-09-18 · checked 2026-09-02
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Teveten · DIN 02240432 Manufacturer: Solvay Pharma Inc.; listing date 2002-07-29 Health Canada: Cancelled post market since 2023-09-18 · brand TEVETEN · ATC C09CA02 EPROSARTAN · form Tablet · route Oral · ingredients EPROSARTAN (EPROSARTAN MESYLATE) 400 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Teveten: Formulary list price $0.7790/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.7790 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63981 · Verify on the e-Formulary ↗ (DIN 02240432)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02240432). DIN 02240432: Teveten Raw flags: chronicUseMed=Y, dinStatus=E, sec3=Y Item: 240800247; group id 325; item number 0723; lccId None; manufacturer id SPH Source form: Tab; strength: 400mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); DIN status E, meaning unconfirmed Source prices (unrounded): $0.7790; ministry $0.7790 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02240432 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63981
Shortage status: resolved shortage (ended 2023-08-30); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02240432
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.

Teveten · DIN 02243942 · 600mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.Discontinued 2023-09-18 · checked 2026-09-02
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Teveten · DIN 02243942 Manufacturer: Solvay Pharma Inc.; listing date 2002-07-29 Health Canada: Cancelled post market since 2023-09-18 · brand TEVETEN · ATC C09CA02 EPROSARTAN · form Tablet · route Oral · ingredients EPROSARTAN (EPROSARTAN MESYLATE) 600 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Teveten: Formulary list price $1.1910/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1910 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67885 · Verify on the e-Formulary ↗ (DIN 02243942)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243942). DIN 02243942: Teveten Raw flags: chronicUseMed=Y, dinStatus=E, sec3=Y Item: 240800252; group id 325; item number 0724; lccId None; manufacturer id SPH Source form: Tab; strength: 600mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); DIN status E, meaning unconfirmed Source prices (unrounded): $1.1910; ministry $1.1910 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243942 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67885
Shortage status: resolved shortage (ended 2020-11-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243942
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.

EPROSARTAN MESYLATE & HYDROCHLOROTHIAZIDE

All products: general benefit

Other products in the same Health Canada class (C09CA) — coverage varies; not interchangeable

  • Candesartan cilexetil (Atacand): general benefit
  • Irbesartan (Avapro): general benefit, Not a benefit
  • Losartan (Cozaar): general benefit
  • Olmesartan medoxomil (Olmetec): general benefit
  • Telmisartan (Micardis): general benefit
  • Valsartan (Diovan): general benefit, Not a benefit

Teveten Plus · DIN 02253631 · 600mg & 12.5mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.Discontinued 2023-09-18 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Teveten Plus · DIN 02253631 Manufacturer: Solvay Pharma Inc.; listing date 2005-05-25 Health Canada: Cancelled post market since 2023-09-18 · brand TEVETEN PLUS · ATC C09DA02 EPROSARTAN AND DIURETICS, C09DA02 EPROSARTAN AND DIURETICS · form Tablet · route Oral · ingredients EPROSARTAN (EPROSARTAN MESYLATE) 600 MG, HYDROCHLOROTHIAZIDE 12.5 MG · company Bgp pharma ulc · schedule Prescription
Check this DIN again · Health Canada product record

Teveten Plus: Formulary list price $1.1910/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.1910 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73859 · Verify on the e-Formulary ↗ (DIN 02253631)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02253631). DIN 02253631: Teveten Plus Raw flags: chronicUseMed=Y, dinStatus=E, sec3=Y Item: 240800259; group id 326; item number 0725; lccId None; manufacturer id SPH Source form: Tab; strength: 600mg & 12.5mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); DIN status E, meaning unconfirmed Source prices (unrounded): $1.1910; ministry $1.1910 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02253631 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73859
Shortage status: discontinued (2023-08-30, reported by BGP PHARMA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02253631
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2023-09-18 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:08 Hypotensive Drugs (For Diuretics See 40:28)) and how they are covered

Matched class: 24:08 Hypotensive Drugs (For Diuretics See 40:28)

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANDESARTAN CILEXETIL, CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE, CILAZAPRIL & HYDROCHLOROTHIAZIDE, LABETALOL HCL, LOSARTAN POTASSIUM, LOSARTAN POTASSIUM & HYDROCHLOROTHIAZIDE, MINOXIDIL, OLMESARTAN MEDOXOMIL, OLMESARTAN MEDOXOMIL & HYDROCHLOROTHIAZIDE, PERINDOPRIL ERBUMINE, PERINDOPRIL ERBUMINE & INDAPAMIDE, PINDOLOL & HYDROCHLOROTHIAZIDE, TELMISARTAN, TELMISARTAN & AMLODIPINE BESYLATE, TELMISARTAN & HYDROCHLOROTHIAZIDE, VALSARTAN & HYDROCHLOROTHIAZIDE Some products covered without a code (check the product listing): ATENOLOL & CHLORTHALIDONE, BENAZEPRIL, CAPTOPRIL, CILAZAPRIL, CLONIDINE HCL, DOXAZOSIN MESYLATE, ENALAPRIL MALEATE, FELODIPINE, FOSINOPRIL SODIUM, HYDRALAZINE HCL, IRBESARTAN, IRBESARTAN & HYDROCHLOROTHIAZIDE, LISINOPRIL, LISINOPRIL & HYDROCHLOROTHIAZIDE, METHYLDOPA, NIFEDIPINE, PINDOLOL, PRAZOSIN HCL, QUINAPRIL, QUINAPRIL & HYDROCHLOROTHIAZIDE, RAMIPRIL, RAMIPRIL & HYDROCHLOROTHIAZIDE, TERAZOSIN HCL, TRANDOLAPRIL, VALSARTAN, VERAPAMIL HCL 24:08 Hypotensive Drugs (For Diuretics See 40:28)

CANDESARTAN CILEXETIL

· 59 products · General benefit · strengths: 4mg, 8mg, 16mg, 32mg · Tab

IRBESARTAN

· 41 products · Listed, not a benefit (1), General benefit (40) · strengths: 75mg, 150mg, 300mg · Tab

LOSARTAN POTASSIUM

· 42 products · General benefit · strengths: 25mg, 50mg, 100mg · Tab

OLMESARTAN MEDOXOMIL

· 22 products · General benefit · strengths: 20mg, 40mg · Tab

TELMISARTAN

· 25 products · General benefit · strengths: 40mg, 80mg · Tab

VALSARTAN

· 38 products · Off-Formulary Interchangeable, not an ODB benefit (10), General benefit (28) · strengths: 40mg, 80mg, 160mg, 320mg · Tab

ATENOLOL & CHLORTHALIDONE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50 & 25mg, 100 & 25mg · Tab

BENAZEPRIL

· 6 products · Listed, not a benefit (3), General benefit (3) · strengths: 5mg, 10mg, 20mg · Tab

CANDESARTAN CILEXETIL & HYDROCHLOROTHIAZIDE

· 21 products · General benefit · strengths: 16mg & 12.5mg, 32mg & 12.5mg, 32mg & 25mg · Tab

CAPTOPRIL

· 14 products · Limited Use, codes 707, 723 (2), Listed, not a benefit (4), General benefit (8) · strengths: 5mg/5mL, 25mg/5mL, 12.5mg, 25mg, 50mg, 100mg · Oral Sol, Tab

CILAZAPRIL

· 8 products · Listed, not a benefit (2), General benefit (6) · strengths: 1mg, 2.5mg, 5mg · Tab

CILAZAPRIL & HYDROCHLOROTHIAZIDE

· 2 products · General benefit · strengths: 5mg/12.5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 24:08 and 34 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Availability

Teveten Plus · DIN 02253631 Shortage status: discontinued (2023-08-30, reported by BGP PHARMA ULC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02253631

Check this DIN again